IFP Advisors’s GSK GSK Stock Holding History

IFP Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Buy	22,034 +142	+0.6%	+$7.51K	0.02%	680
2026 Q1	$1.21M	Sell	21,892 -620	-3%	-$33.6K	0.03%	610
2025 Q4	$1.1M	Buy	22,512 +11,243	+100%	+$524K	0.02%	618
2025 Q3	$486K	Sell	11,269 -996	-8%	-$38.9K	0.01%	872
2025 Q2	$471K	Buy	12,265 +480	+4%	+$18.3K	0.01%	857
2025 Q1	$457K	Sell	11,785 -607	-5%	-$22.2K	0.01%	803
2024 Q4	$419K	Buy	12,392 +6,578	+113%	+$237K	0.01%	806
2024 Q3	$238K	Sell	5,814 -1,828	-24%	-$74.8K	0.01%	1008
2024 Q2	$294K	Buy	7,642 +1,158	+18%	+$48.7K	0.01%	847
2024 Q1	$278K	Sell	6,484 -154	-2%	-$6.35K	0.01%	840
2023 Q4	$246K	Sell	6,638 -397	-6%	-$14.3K	0.01%	857
2023 Q3	$255K	Buy	7,035 +1,312	+23%	+$46.6K	0.01%	855
2023 Q2	$204K	Sell	5,723 -1,267	-18%	-$45.4K	0.01%	1016
2023 Q1	$307K	Sell	6,990 -9,283	-57%	-$325K	0.01%	765
2022 Q4	$732K	Buy	16,273 +5,100	+46%	+$170K	0.02%	740
2022 Q3	$521K	Buy	11,173 +2,180	+24%	+$82.6K	0.01%	911
2022 Q2	$520K	Hold	8,993	–	–	0.02%	833
2022 Q1	$520K	Buy	8,993 +4,719	+110%	+$256K	0.02%	833
2021 Q4	$238K	Buy	4,274 +206	+5%	+$10.7K	﹤0.01%	872
2021 Q3	$194K	Buy	4,068 +140	+4%	+$7.03K	﹤0.01%	966
2021 Q2	$194K	Sell	3,928 -85	-2%	-$4.08K	﹤0.01%	921
2021 Q1	$180K	Sell	4,013 -467	-10%	-$21.2K	﹤0.01%	886
2020 Q4	$206K	Sell	4,480 -250	-5%	-$11.5K	0.01%	788
2020 Q3	$225K	Buy	4,730 +222	+5%	+$11.1K	0.01%	665
2020 Q2	$229K	Sell	4,508 -227	-5%	-$11.6K	0.02%	614
2020 Q1	$220K	Sell	4,735 -1,447	-23%	-$77.2K	0.02%	554
2019 Q4	$363K	Sell	6,182 -974	-14%	-$54.2K	0.03%	498
2019 Q3	$377K	Buy	+7,156	New	+$368K	0.03%	565
2019 Q1	$316K	Sell	6,105 -20,322	-77%	-$1.02M	0.04%	367
2018 Q4	$1.26M	Sell	26,427 -3,480	-12%	-$171K	0.08%	288
2018 Q3	$1.5M	Buy	29,907 +9,110	+44%	+$463K	0.06%	328
2018 Q2	$1.05M	Sell	20,797 -1,093	-5%	-$55K	0.04%	404
2018 Q1	$971K	Hold	21,890	–	–	0.04%	402
2017 Q4	$971K	Sell	21,890 -11,424	-34%	-$528K	0.04%	402
2017 Q3	$1.69M	Sell	33,314 -1,076	-3%	-$54.6K	0.07%	303
2017 Q2	$1.85M	Buy	34,390 +1,717	+5%	+$91.5K	0.08%	282
2017 Q1	$1.72M	Buy	32,673 +1,024	+3%	+$51.9K	0.08%	287
2016 Q4	$1.52M	Buy	31,649 +4,627	+17%	+$229K	0.07%	296
2016 Q3	$1.46M	Buy	27,022 +1,788	+7%	+$98K	0.08%	278
2016 Q2	$1.37M	Buy	25,234 +19,129	+313%	+$1.01M	0.08%	284
2016 Q1	$316K	Sell	6,105 -11,314	-65%	-$564K	0.04%	367
2015 Q4	$879K	Buy	+17,419	New	+$888K	0.06%	340

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IFP Advisors's GSK Position: Q2 2026 in Review

IFP Advisors increased its GSK (GSK) stake by 0.65% in Q2 2026, buying an estimated $7.51K and bringing the position to 22,034 shares worth $1.16M. The position accounts for 0.02% of the portfolio, ranked #680.

IFP Advisors first reported a position in GSK in Q4 2015 and has held it in 42 quarters since. The position peaked at $1.85M in Q2 2017. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

IFP Advisors held 22,034 shares of GSK worth $1.16M as of Q2 2026.
IFP Advisors bought 142 GSK shares in Q2 2026, an estimated $7.51K.
GSK made up 0.02% of IFP Advisors's portfolio in Q2 2026, its #680 holding.
IFP Advisors first reported a position in GSK in Q4 2015 and has held it in 42 quarters since.
IFP Advisors's GSK position peaked at $1.85M in Q2 2017.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.